Bleeding and freezing cases are the lowest in India following the COVID vaccine, according to a report submitted to the Ministry of Health and Family Welfare by the National AEFI (Post-Immunization Adverse Event) Committee.

In some countries warnings have been raised about “embolic and thrombotic events” after the vaccination on 20 March 2021, particularly the AstraZeneca-Oxford vaccine [Covshield] in India. It was decided to make an urgent and in-depth analysis of adverse events (AEs) occurring in India.

As of April 03, 2021 (Govshield - 68,650,819; Kovacsin - 6,784,562). Of these, 65,944,106 were the first dose and 9,491,275 the second dose.
Since the inception of the COVID-19 vaccine campaign - more than 23,000 adverse events have been reported through the CO-WIN site in 753 districts of the country.

26 of these cases are said to be possible thromboembolic events. A clot forms in a blood vessel (clot forms in a blood vessel) that can loosen and rupture and be carried away by the bloodstream.

No possible thromboembolic events have been reported with covaxin vaccine.

AEFI data in India show a very low but definite risk of thromboembolic events. The reported rate of these events in India is about 0.61 / million (1 million is equal to 10 lakhs). This is 4 cases / million dose in the UK. Germany reported 10 cases per one million doses.

Compared to people of European descent, the risk is almost 70 percent lower for people of South and Southeast Asian descent. It is important to know that thromboembolic events continue to occur in the general population.

MOHFW has been advising health workers and vaccine users individually to encourage people to be aware of suspicious thromboembolic symptoms within 20 days of receiving any COVID-19 vaccine (especially Govshield):

Suffocation;
Chest pain;
Pain in limbs / pain in compression of limbs or swelling in limbs (arm or calf);
Many, pinhead-sized red spots or abrasions on the skin in the area beyond the injection site;
Persistent abdominal pain with or without vomiting;
Absence or previous history of seizures or vomiting;
Severe and persistent headache with or without vomiting (in the absence of a previous history of migraine or chronic headache);
Weakness / paralysis of the limbs or any particular side or part of the body (including the face);
Persistent vomiting for no apparent reason;
Blurred vision or pain in the eyes or having double vision;
A change in mood or a state of confusion or depression
Any other symptom or health condition that is of concern to the recipient or family
GoviShield, the COVID-19 vaccine, is detailed with great potential to prevent infections and reduce mortality due to COVID-19 worldwide and in India. 13.4 crore doses of cow shield vaccine have been given in India till 20 April 2021 MoHFW continues to monitor the safety of all COVID-19 vaccines and encourages the reporting of suspected adverse events.